COMP <GO>
KROS vs LLY // EV/EBITDA & P/E VALUATION
Keros Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: KROS 3
— LLY 6
■ METRIC PARITY
LAST: $11.04 (-2.82%) • MKT CAP: $225.2M
valuation
—
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KROS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KROS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 32.36% | +52.64 | KROS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.30% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 27.70% | 40.21% | -12.51 | LLY | /operating-margins <GO> |
| Net Profit Margin | 35.70% | 31.90% | +3.80 | KROS | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 45.51% | +134.49 | KROS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.31 | 9.29 | -4.98 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.6 | 66.6 | -26.03 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $225.2M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KROS REV | LLY REV | KROS GROSS % | LLY GROSS % | KROS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $244.1M | $65.18B | — | 83.0% | $106.0M | $16.81B |
| FY 2024 | $3.5M | $45.04B | — | 81.3% | -$162.8M | $8.82B |
| FY 2023 | $151.0K | $34.12B | — | 79.3% | -$124.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KROS // BETA —
LLY // BETA 0.51